Becaplermin gel in the treatment of diabetic neuropathic foot ulcers

Nikolaos Papanas, Efstratios MaltezosOutpatient Clinic of Obesity, Diabetes and Metabolism at the Second Department of Internal Medicine, Democritus University of Thrace, GreeceAbstract: Diabetic foot ulcers remain a major cause of morbidity. Significant progress has been accomplished in ulcer heali...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nikolaos Papanas, Efstratios Maltezos
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/a9b306388c774910a7d4f184daf106e0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a9b306388c774910a7d4f184daf106e0
record_format	dspace
spelling	oai:doaj.org-article:a9b306388c774910a7d4f184daf106e02021-12-02T00:33:24ZBecaplermin gel in the treatment of diabetic neuropathic foot ulcers1178-1998https://doaj.org/article/a9b306388c774910a7d4f184daf106e02008-06-01T00:00:00Zhttps://www.dovepress.com/becaplermin-gel-in-the-treatment-of-diabetic-neuropathic-foot-ulcers-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Nikolaos Papanas, Efstratios MaltezosOutpatient Clinic of Obesity, Diabetes and Metabolism at the Second Department of Internal Medicine, Democritus University of Thrace, GreeceAbstract: Diabetic foot ulcers remain a major cause of morbidity. Significant progress has been accomplished in ulcer healing by improved management of both ischemia and neuropathy in the diabetic foot. Nevertheless, there is a vital need for further improvement. Becaplermin gel represents an important therapeutic advance for diabetic neuropathic foot ulcers with adequate blood supply. Randomized controlled trials have shown that it is effective in increasing healing rates. However, this efficacy has not translated to positive clinical experience, and the drug is not widely used. Moreover, becaplermin is an expensive medication. Even though it has repeatedly been estimated as cost-effective, its high cost may be prohibitive for some clinicians, especially in developing countries. Clearly, further work is needed to clarify whether use of becaplermin is justified in everyday clinical practice. Future research also needs to assess the potential room for improvement with becaplermin, for instance by combination with other growth factors or by exploring alternative modes of drug delivery.Keywords: becaplermin, diabetes mellitus, diabetic foot, neuropathy, PDGFNikolaos PapanasEfstratios MaltezosDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 233-240 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Nikolaos Papanas Efstratios Maltezos Becaplermin gel in the treatment of diabetic neuropathic foot ulcers
description	Nikolaos Papanas, Efstratios MaltezosOutpatient Clinic of Obesity, Diabetes and Metabolism at the Second Department of Internal Medicine, Democritus University of Thrace, GreeceAbstract: Diabetic foot ulcers remain a major cause of morbidity. Significant progress has been accomplished in ulcer healing by improved management of both ischemia and neuropathy in the diabetic foot. Nevertheless, there is a vital need for further improvement. Becaplermin gel represents an important therapeutic advance for diabetic neuropathic foot ulcers with adequate blood supply. Randomized controlled trials have shown that it is effective in increasing healing rates. However, this efficacy has not translated to positive clinical experience, and the drug is not widely used. Moreover, becaplermin is an expensive medication. Even though it has repeatedly been estimated as cost-effective, its high cost may be prohibitive for some clinicians, especially in developing countries. Clearly, further work is needed to clarify whether use of becaplermin is justified in everyday clinical practice. Future research also needs to assess the potential room for improvement with becaplermin, for instance by combination with other growth factors or by exploring alternative modes of drug delivery.Keywords: becaplermin, diabetes mellitus, diabetic foot, neuropathy, PDGF
format	article
author	Nikolaos Papanas Efstratios Maltezos
author_facet	Nikolaos Papanas Efstratios Maltezos
author_sort	Nikolaos Papanas
title	Becaplermin gel in the treatment of diabetic neuropathic foot ulcers
title_short	Becaplermin gel in the treatment of diabetic neuropathic foot ulcers
title_full	Becaplermin gel in the treatment of diabetic neuropathic foot ulcers
title_fullStr	Becaplermin gel in the treatment of diabetic neuropathic foot ulcers
title_full_unstemmed	Becaplermin gel in the treatment of diabetic neuropathic foot ulcers
title_sort	becaplermin gel in the treatment of diabetic neuropathic foot ulcers
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/a9b306388c774910a7d4f184daf106e0
work_keys_str_mv	AT nikolaospapanas becaplermingelinthetreatmentofdiabeticneuropathicfootulcers AT efstratiosmaltezos becaplermingelinthetreatmentofdiabeticneuropathicfootulcers
_version_	1718403697779671040

Becaplermin gel in the treatment of diabetic neuropathic foot ulcers

Ejemplares similares